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IMPACT OF AN INCREASE IN PRESCRIPTION
CO-PAYMENT ON DRUG UTILIZATION
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Double-digit increases in pharmacy expenditures have
induced health plan administrators to pursue alternative
methods to control beneﬁts. Shifting the burden to con-
sumers in the form of higher prescription co-payments is
one popular strategy. However, the impact of increased
cost sharing is not always clear and may vary among 
therapeutic classes.
OBJECTIVE: The objective of this study was to assess
the impact of a $10 co-payment increase in a private, 
for-proﬁt managed care organization.
METHODS: This analysis examined changes in drug 
utilization one year prior to the co-payment increase 
with those one year after the increase for two therapeu-
tic classes: non-sedating antihistamines and nasal
steroids. Both descriptive statistics and paired t-tests were
used to assess the impact of prescription utilization after
the copay change. Also, relative price effects were mea-
sured as arc elasticities.
RESULTS: The total number of prescriptions dispensed
during the two years was 6952 for non-sedating antihis-
tamines and 1806 for nasal steroids. After increasing the
prescription co-payment, 470 more non-sedating antihis-
tamine prescriptions were dispensed, although fewer
reﬁlls were reported. In contrast, a total of 108 fewer
nasal steroid prescriptions were dispensed after increas-
ing the prescription co-payment. Similar to the anti-
histamines, fewer nasal steroid prescriptions were reﬁlled
in 1999. There was a statistically signiﬁcant average
decrease of 0.44 non-sedating antihistamine prescriptions
noted in 1999, compared to 1998 (p < 0.0001). In 
contrast, there was no change in the average number of
nasal steroids dispensed in 1999 compared to 1998. Non-
sedating antihistamine reﬁlls were less elastic with an
unadjusted arc elasticity of -0.26 while nasal steroids
were more responsive to the co-payment change with an
unadjusted arc elasticity of -0.81.
CONCLUSION: Based upon our results, a $10 dollar
increase in patient cost sharing does not affect utilization
equally across therapeutic drug classes.
PHP40
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OBJECTIVES: Despite recent blood safety advances, 
a residual risk of pathogen transmission during 
platelet transfusion remains. Pathogen inactivation using
INTERCEPT Platelet System (IPS) has been developed to
further reduce these risks. This study assessed the cost
effectiveness of IPS for pathogen inactivation of pooled
random-donor and single-donor apheresis platelet 
(RDP-PI and SDP-PI) transfusions.
METHODS: A literature-based decision analysis model
assessed the cost effectiveness of IPS in US patients receiv-
ing SDPs or RDPs. For the baseline analyses, patients
were 10-year-old female with acute lymphocytic leukemia
(ALL), a 50-year-old female with non-Hodgkin’s lym-
phoma (NHL), and a 60-year-old male undergoing heart
surgery (CABG). Pathogen exposure included HIV, HCV,
HBV, HTLV-I, bacterial sepsis and new emergent viruses
(such as a highly prevalent HIV- or hepatitis-like virus).
The model compared projected QALY and costs for
patients receiving untreated vs. treated platelets. Univari-
ate sensitivity analyses were performed to test robustness.
RESULTS: When minimal beneﬁts were included, 
incremental cost per QALY of RPD-PI vs. untreated 
RDPs were $69,000 (ALL), $132,000 (CABG) and
$202,000 (NHL). Corresponding ﬁgures for SDP-PI were
$666,000, $1,420,000, and $2,234,000. When addi-
tional beneﬁts such as processing beneﬁts (e.g. shelf-life
extension) and new emergent viruses (highly prevalent
HIV-like virus) were included, RDP-PI led to increased
survival and reductions in costs ($601 for ALL, $86 for
CABG, and $1,030 for NHL) whereas the incremental
cost per QALY for SDP-PI ranged from $11,000 (ALL),
$94,000 (NHL), and $76,000 (CABG).
CONCLUSIONS: The cost effectiveness of IPS compares
favorably with that of other blood safety interventions
(e.g. NAT, ELISA testing) and injury prevention strategies
(e.g. school bus seat belt use) that are widely accepted as
valuable by society. Thus, platelet inactivation with IPS is
a relatively cost-effective strategy to ensure the safety of
platelet transfusions and a valuable insurance against the
threat of new emerging pathogens.
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OBJECTIVES: Vaccination is one of the most signiﬁcant
public health interventions in the past century, sparing
millions of people from infectious diseases. While most
agree that vaccination is one of the most accepted and
cost-effective public health practices worldwide, vaccines
continue to be underused and undervalued, and vaccine-
preventable diseases remain a threat to world health.
There has been less attention to the importance and 
value of vaccination in general. This paper will review the
global value of vaccination, the effectiveness of vaccina-
tion initiatives, and the steps necessary to sustain progress
